# Efficacy and Safety of Apremilast in Psoriasis

> **NCT06032858** · PHASE4 · COMPLETED · sponsor: **Ghurki Trust and Teaching Hospital** · enrollment: 30 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast 30mg

## Key facts

- **NCT ID:** NCT06032858
- **Lead sponsor:** Ghurki Trust and Teaching Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-06
- **Primary completion:** 2023-07-10
- **Final completion:** 2023-08-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06032858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06032858, "Efficacy and Safety of Apremilast in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06032858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*